Abstract |
Urapidil is an antagonist of postsynaptic alpha 1 receptors, which leads to a diminution of the increased blood pressure by reducing the peripheral vascular resistance. With this pilot study we examined, whether it is possible to reduce the pregnancy-induced-hypertension with urapidil postpartum. The postpartum dosage of dihydralazine was diminished step by step and finally discontinued. We started i.v. treatment with urapidil at a diastolic blood pressure of more than 100 mm Hg. We observed a declining blood pressure in all cases without any tachycardia or serious side effects. Further studies will have to classify the rank of urapidil in the treatment of hypertension in preeclampsia.
|
Authors | J Wacker, J Müller, E M Grischke, R Unkels, G Bastert |
Journal | Zentralblatt fur Gynakologie
(Zentralbl Gynakol)
Vol. 116
Issue 5
Pg. 271-3
( 1994)
ISSN: 0044-4197 [Print] Germany |
Vernacular Title | Antihypertensive Therapie bei schwangerschaftsinduzierter Hypertonie (SIH) mit Urapidil. |
PMID | 8023622
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antihypertensive Agents
- Piperazines
- urapidil
- Dihydralazine
|
Topics |
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Blood Pressure
(drug effects)
- Blood Pressure Monitors
- Dihydralazine
(therapeutic use)
- Drug Administration Schedule
- Female
- Heart Rate
(drug effects)
- Humans
- Hypertension
(drug therapy)
- Infusions, Intravenous
- Maternal-Fetal Exchange
(drug effects)
- Pilot Projects
- Piperazines
(adverse effects, therapeutic use)
- Pre-Eclampsia
(drug therapy)
- Pregnancy
- Pregnancy Complications, Cardiovascular
(drug therapy)
- Puerperal Disorders
(drug therapy)
|